BrainsWay (NASDAQ:BWAY) versus Biotricity (NASDAQ:BTCY) Head-To-Head Review

Biotricity (NASDAQ:BTCY) and BrainsWay (NASDAQ:BWAY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.

Valuation & Earnings

This table compares Biotricity and BrainsWay”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	0.77	-$14.09 million	($1.74)	-0.24
BrainsWay	$36.43 million	4.68	-$4.20 million	$0.05	204.60

BrainsWay has higher revenue and earnings than Biotricity. Biotricity is trading at a lower price-to-earnings ratio than BrainsWay, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Biotricity and BrainsWay’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-117.42%	N/A	-242.92%
BrainsWay	1.67%	1.45%	0.96%

Institutional and Insider Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 30.1% of BrainsWay shares are owned by institutional investors. 10.1% of Biotricity shares are owned by company insiders. Comparatively, 19.0% of BrainsWay shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Biotricity and BrainsWay, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
BrainsWay	0	1	3	0	2.75

BrainsWay has a consensus price target of $13.17, suggesting a potential upside of 28.71%. Given BrainsWay’s stronger consensus rating and higher probable upside, analysts plainly believe BrainsWay is more favorable than Biotricity.

Volatility & Risk

Biotricity has a beta of 1.33, meaning that its stock price is 33% more volatile than the S&P 500. Comparatively, BrainsWay has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.

Summary

BrainsWay beats Biotricity on 13 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.